market and provide drugs that are equivalent to the innovator’s drugs, however, at a
significantly lower price. Therefore, manufacturers are focusing on developing new and
innovative products to sustain in the competitive market.
Increasing prevalence of wide range of disease such as cancer, cardiovascular, and CNS-related
disorders with patent expiration of blockbuster drugs are some of the driving factors for growth
of the drug discovery market. According to the World Cancer Research Fund International,
2015, an estimated 124,000 new cases of myeloma were diagnosed globally in 2015, which
accounted for 0.8% of the total cancer cases. The mortality rate of the disease is around 0.9%
of all cancer deaths, accounting for 87,000 deaths each year. Therefore, key manufacturers are
actively involved in the development of immunotherapies targeting B-cell maturation antigen
(BCMA) such as chimeric antigen receptor T-cells (CAR-T cells), bispecific antibodies, and
antibody drug conjugates (ADCs). For instance, in 2012, the University of Pennsylvania and
Novartis entered into an exclusive global research and licensing agreement to study and
commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR)
technologies. In 2016, Juno Therapeutics entered into a licensing agreement with Memorial
Sloan Kettering Cancer Center (MSKCC) and Eureka Therapeutics for developing CAR T cell
immunotherapy against multiple novel targets.
Drug Discovery Market - Regional Insights:
North America accounted for the largest share in the drug discovery market, followed by
Europe market in 2016. This is attributed to presence of a large number of top pharmaceutical
and biotech companies, Pfizer, Inc., Merck, GlaxoSmithKline, Novartis and many more in this
region. Furthermore, favorable regulatory framework and regulatory policies for investors for
research and development of new drugs augments growth of drug discovery market in the
region. The US Regulatory Framework provides for 3 distinct regulatory approval pathways
outlined in the Food, Drug, and Cosmetics Act (FD&C Act), which allows the registration of
novel compounds, new drugs containing similar ingredients to previously approved products and
generic copies of previously approved products in systematic way helping the pharmaceutical
companies to gain approval over the new drugs.
Report includes chapters
• Drug Discovery Market
• Drug Discovery Market
Opportunity Map (COM)
• Drug Discovery Market
which deeply display the following deliverable about industry :
Research Objective and Assumption
Purview - Report Description, Executive Summary, and Coherent
Dynamics, Regulations, and Trends Analysis - Market Dynamics,